Description

TriGH is a premium triple-peptide growth hormone research formulation combining Ipamorelin, CJC-1295, and Tesamorelin for comprehensive, multi-mechanism GH axis investigations. This advanced stack is designed for laboratories requiring the most thorough analytical approach to growth hormone secretion, hypothalamic-pituitary signaling, and somatotropic biology. Ipamorelin provides selective ghrelin receptor-mediated GH stimulation; CJC-1295 extends GHRH receptor engagement for sustained GH pulse support; and Tesamorelin — a stabilized GHRH analogue — contributes distinct hypothalamic pituitary signaling activity and visceral adipose-related metabolic research potential. Together, the three compounds create a layered research profile that mirrors and extends the natural GH regulatory axis, making TriGH ideal for sophisticated endocrine modeling, metabolic investigation, and advanced growth hormone research.